Trial Profile
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Oct 2023
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Short stature
- Focus Adverse reactions
- Sponsors Ipsen
- 06 Mar 2023 Planned End Date changed from 1 Dec 2027 to 31 Dec 2027.
- 06 Mar 2023 Planned primary completion date changed from 1 Dec 2027 to 31 Dec 2027.
- 06 Dec 2021 Planned number of patients changed from 330 to 500.